AfricaHealthNews

Zimbabwe approves long-acting HIV prevention drug

The HIV drug has received regulatory approval in two other countries, the United States of America (USA) and Australia

Zimbabwe has become the first county in Africa to approve a long-acting injectable drug that prevents HIV transmission.

The first two injections of Cabotegraviror CAB-LA are administered four weeks apart, followed by an injection every eight weeks.

The drug has received regulatory approval in two other countries, the US and Australia.

Zimbabwe will begin rolling out the drug after regulators approved its use. The authorities say it will provide a crucial layer of protection for risk groups.

Large scale studies of the drug showed 79% reduction in HIV risk compared with oral pre-exposure prophylaxis, according to the World Health Organisation (WHO).

Zimbabwe approved a long-acting HIV preventative vaginal ring earlier this year.

While African countries have dramatically reduced the number of new HIV infections, adolescent girls and young women remain at risk accounting for 63% of new infections last year.

Asaase Radio 99.5 broadcasts on radio via 99.5 in Accra, 98.5 in Kumasi, 99.7 in Tamale, 100.3 in Cape Coast and on our affiliates Bawku FM 101.5 in Bawku, Beats FM 99.9 in Bimbilla, Somua FM 89.9 in Gushegu, Stone City 90.7 in Ho, Mining City 89.5 in Tarkwa and Wale FM 106.9 in Walewale
Tune in or log on to broadcasts 
online: www.asaaseradio.com, Sound Garden and TuneIn
Follow us on Twitter: @asaaseradio995
Live streaming: facebook.com/asaaseradio99.5. Also on YouTube: Asaase Radio Official.
Join the conversation. Call: 020 000 9951 or 059 415 7777. Or WhatsApp: 020 000 0995.

#AsaaseRadio

Source
BBC
Show More

Related Articles

Back to top button

Adblock Detected

ALLOW OUR ADS